Ríos-Quintana R, Estrada-Hernández LO

Language: Spanish
References: 10
Page: 173-187
PDF size: 605.23 Kb.

ABSTRACT

Objective: To analyze drug-adverse reactions related to the administration of non-selective non-steroidal anti-inflammatory drugs (NSAIDS) reported to the National Pharmacovigilance Center from 2011 to 2014.
Material and Method: A study was done in which for the descriptive analysis was used the database of the National Pharmacovigilance Center 2011-2014 containing the drug-adverse reactions related to the administration of analgesic drugs coming from the different members of the Permanent Program of Pharmacovigilance, that were grouped according to: age and sex of patient, proceeding of the drug-adverse reaction, suspect active principle, severity and causality of reaction.
Results: 4553 drug-adverse reactions were related to the administration of an NSAID (3.9%). Metamizol was the most reported with 21.1% of the total of adverse reaction registered for this group of drugs.
Conclusions: Metamizol was the drug with more drug-adverse reactions reported. The dermatological reactions of importance (toxic epidermal necrolysis, Stevens-Johnson syndrome and Lyell syndrome) were higher reported with nimesulide.

REFERENCES

1. Administration, F. a. (13 de enero de 2011). Food and Drug Administration. Obtenido de FDA Press Release: FDA limits acetaminophen in prescription combination products; requires liver toxicity warnings : http://www. fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm239894.htm

2. Administration, F. a. (13 de enero de 2011). Food and Drug Administration Home Page. Obtenido de FDA Consumer Update: New Steps Aimed at Cutting Risks from Acetaminophen : http://www.fda.gov/ForConsumers/ ConsumerUpdates/ucm239747.htm

3. Administration, F. a. (28 de abril de 2014). Food and Drug Administration. Obtenido de FDA reminds health care professionals to stop dispensing prescription combination drug products with more than 325 mg of acetaminophen: http://www.fda.gov/Drugs/DrugSafety/ucm394916.htm

4. Administration, F. a. (26 de marzo de 2014). Food and Drug Administration Home Page. Obtenido de All manufacturers of prescription combination drug products with more than 325 mg of acetaminophen have discontinued marketing: http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ ucm390509.htm

5. Farmacovigilancia, C. N. (14 de octubre de 2014). Comisión Federal para la Protección contra Riesgos Sanitarios. Obtenido de Comisión Federal para la Protección contra Riesgos Sanitarios: file:///C:/Users/rrios/Downloads/Comunicado% 20Diclofenaco%20correcion%20(4).pdf

6. Farmacovigilancia, C. N. (07 de enero de 2015). Comisión Federal para la Protección contra Riesgos Sanitarios. Obtenido de Comunicado dirigido a los profesionales de la salud y a la población en general: Uso para consumidores de antigripales y medicamentos contra el dolor.: file:///C:/ Users/rrios/Downloads/COMUNICADO%20PARACETAMOL180215% 20(4).pdf

7. Farmacovigilancia, C. N. (2015 de junio de 2015). Comisión Federal para la Protección contra Riesgos Sanitarios. Obtenido de Comunicado dirigido a los profesionales de la salud y a la población en general: Riesgo cardiovascular asociado a dosis altas de Ibuprofeno.: file:///C:/Users/ rrios/Downloads/comunicado%20ibuprofeno%20(3).pdf

8. Medicamento, A. E. (06 de mayo de 2002). Agencia Española del Medicamento. Obtenido de Nimesulida: suspensión cautelar de comercialización: http://www.aemps.gob.es/ informa/notasInformativas/medicamentosUsoHumano/ seguridad/2002/NI_2002-03_nimesulida.htm

9. PARF), R. P. (s.f.). Red Panamericana para la Armonización de la Reglamentación Farmacéutica (Red PARF). Obtenido de Señales en Farmacovigilancia: file:///C:/Users/rrios/ Downloads/Consulta_publica_senales_en_farmacovigilancia% 20(6).pdf

10. Sanitarios, C. F. (2013 de enero de 2013). NOM-220- SSA1-2012 . Obtenido de NOM-220-SSA1-2012. Instalación y Operación de la Farmacovigilancia : http://www. dof.gob.mx/nota_detalle.php?codigo=5284236&fec ha=07/01/2013.